0.9638 0.014 (1.45%) | 02-14 16:00 | |||||||||||||
|
|
Short term | ![]() |
|||
Mid term | ![]() ![]() ![]() |
|||
Targets | 6-month : | 1.23 | 1-year : | 1.33 |
Resists | First : | 1.05 | Second : | 1.13 |
Pivot price | 0.98 ![]() |
|||
Supports | First : | 0.93 | Second : | 0.77 |
MAs | MA(5) : | 0.95 ![]() |
MA(20) : | 1 ![]() |
MA(100) : | 1.08 ![]() |
MA(250) : | 1.38 ![]() |
|
MACD | MACD : | -0.1 ![]() |
Signal : | -0.1 ![]() |
%K %D | K(14,3) : | 15 ![]() |
D(3) : | 14.1 ![]() |
RSI | RSI(14): 45.3 ![]() |
|||
52-week | High : | 2 | Low : | 0.84 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ IMAB ] has closed above bottom band by 37.4%. Bollinger Bands are 48.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
If tomorrow: | Open lower | Open higher |
High: | 0.99 - 1 | 1 - 1 |
Low: | 0.93 - 0.93 | 0.93 - 0.94 |
Close: | 0.95 - 0.96 | 0.96 - 0.97 |
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; TJ107, a recombinant human IL-7, which is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat lymphopenia and cancer immunotherapy; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody for inflammation and CRS-related therapies; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers, as well as TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for solid tumors and TJ-C64B, a tumor-dependent T-cell engager for ovarian and other cancers. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.
Tue, 04 Feb 2025
I-Mab to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference - GlobeNewswire
Tue, 04 Feb 2025
Key Oncology Developments: I-Mab's Strategic Presentation at Major Healthcare Conference - StockTitan
Mon, 03 Feb 2025
Significant layoffs amid I-Mab restructuring - The Pharma Letter
Mon, 13 Jan 2025
I-Mab Biopharma Advances Precision Immuno-Oncology Programs Post-China Divestiture - TipRanks
Wed, 08 Jan 2025
I-Mab Chairman plans $2 million ADS purchase - Investing.com
Wed, 08 Jan 2025
I-Mab Announces Open Market Purchases of Company American Depositary Shares by Board Member - PR Newswire
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 0 (M) |
Shares Float | 82 (M) |
Held by Insiders | 1.1042e+008 (%) |
Held by Institutions | 11.1 (%) |
Shares Short | 533 (K) |
Shares Short P.Month | 0 (K) |
EPS | -1.6925e+008 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0 |
Profit Margin | 0 % |
Operating Margin | -4 % |
Return on Assets (ttm) | 938.2 % |
Return on Equity (ttm) | -29.3 % |
Qtrly Rev. Growth | 3.49e+006 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | -66.41 |
EBITDA (p.s.) | 3.23148e+006 |
Qtrly Earnings Growth | -2.5 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | 0 (M) |
PE Ratio | -0.01 |
PEG Ratio | 0 |
Price to Book value | 0 |
Price to Sales | -0.02 |
Price to Cash Flow | 0.04 |
Dividend | 0 |
Forward Dividend | 591160 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |